BioTuesdays

WB starts Poseida Therapeutics at OP; fair value estimate $39

William Blair launched coverage of Poseida Therapeutics (NASDAQ:PSTX) with an “outperform” rating and fair value estimate of $39. The stock closed at $12.98 on Aug. 3.

“In our view, Poseida’s broad suite of platform technologies competitively positions it well in the cell therapy, gene therapy, and gene editing landscapes, while providing long-term optionality,” writes analyst Raju Prasad. 

Mr. Prasad said the company’s Super piggyBac system allows for non-viral integration of a DNA transgene into a genomic target site, mitigating certain hurdles of viral-based approaches. PiggyBac is complemented by Cas-CLOVER, which combines the ease of use, low cost, and ability to exert multiplex editing associated with CRISPR/Cas9 and the high editing fidelity of an endonuclease system. 

To date, he said Poseida’s autologous CAR-T drug candidate, P-BCMA-101, has shown a comparable safety and efficacy profile to the leading B-cell maturation antigen (BCMA) CAR-T in multiple myeloma with low rates of cytokine release syndromeand neurotoxicity. 

“We anticipate an update from the company’s Phase I expansion study of P-BCMA-101 in the second half of 2020 that will provide additional clinical data and delineate the go-forward path with regard to dose and treatment regimen,” he added. 

The company is also developing an allogeneic BCMA CAR-T drug candidate, P-BCMA-ALLO1, with an IND application expected in late 2020 or early 2021. P- BCMA-ALLO1 is differentiated by a heavy-chain only, humanized binder, licensed from TeneoBio, which “we believe has the potential to show a superior clinical profile,” Mr. Prasad said. 

In addition, “we view Poseida’s autologous anti-prostate-specific membrane antigen CAR- T candidate, P-PSMA-101, in metastatic castrate-resistant prostate cancer as a high-risk, high-reward opportunity, given CAR-T efficacy in solid tumors to date,” he said. Preliminary data are expected in late 2020 or early 2021.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.